4378-55-6

Usage

Uses

Used in Pharmaceutical Research and Development:
5-(3,4-DIMETHOXYPHENYL)-5-OXOVALERIC ACID is utilized as a key intermediate in the synthesis of novel drugs and bioactive molecules, leveraging its distinctive structural properties to enhance the therapeutic potential of new chemical entities.
Used in Organic Synthesis:
In the field of organic synthesis, 5-(3,4-DIMETHOXYPHENYL)-5-OXOVALERIC ACID is employed as a valuable building block, contributing to the creation of complex organic compounds and facilitating advancements in chemical research.
Used in Industrial Chemical Production:
5-(3,4-DIMETHOXYPHENYL)-5-OXOVALERIC ACID is used as a precursor in the manufacturing process of a variety of chemical compounds, underscoring its significance in the industrial sector for the production of diverse products.

InChI:InChI=1/C13H16O5/c1-17-11-7-6-9(8-12(11)18-2)10(14)4-3-5-13(15)16/h6-8H,3-5H2,1-2H3,(H,15,16)

Upstream product

• 108-55-4 glutaric anhydride, 
• 91-16-7 1,2-dimethoxybenzene 
• 101499-71-2 5-(3,4-dimethoxy-phenyl)-5-oxo-valeric acid ethyl ester 
• 53715-97-2 5,5'-oxybis(5-oxopentanoic acid) 
• 1070-62-8 5-ethoxy-5-oxopentanoic acid 

Downstream Products

• 1145-15-9 5-(3,4-dimethoxyphenyl)pentanoic acid 
• 101499-71-2 5-(3,4-dimethoxy-phenyl)-5-oxo-valeric acid ethyl ester 
• 79623-03-3 5-hydroxy-5-(3,4-dimethoxyphenyl)valeric acid δ lactone 
• 54419-21-5 1-(3,4-dimethoxyphenyl)butan-1-one 
• 1609188-58-0 2,3-dimethoxy-5-(2-methoxyphenyl)-8,9-dihydro-7H-benzocycloheptene-6-carboxylic acid 
• 1609188-55-7 2,3-dimethoxy-5-(2-methoxyphenyl)-8,9-dihydro-7H-benzocycloheptene-6-carbaldehyde 
• 220396-72-5 2-(4-ethoxycarbonylbutyl)-4,5-dimethoxybenzenesulfonamide 
• 220396-70-3 2-(4-ethoxycarbonylbutyl)-4,5-dimethoxybenzenesulfonyl chloride 
• 220396-75-8 2-(4-carboxybutyl)-4,5-dimethoxybenzenesulfonamide 
• 874518-45-3 5-(3,4-dimethoxyphenyl)pentanoic acid ethyl ester 
• 131699-22-4 5-(3,4-dimethoxy-phenyl)-5-oxo-pentanoic acid methyl ester 

Relevant academic research and scientific papers

Design and synthesis of 4,5,6,7‐tetrahydro‐1H‐1,2‐diazepin‐7‐one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors

Phosphodiesterase 4 (PDE4) inhibitors have attractive therapeutic potential in respiratory, inflammatory, metabolic and CNS disorders. The present work details the design, chemical exploration and biological profile of a novel PDE4 inhibitor chemotype. A

Synthesis of Medium-Ring-Sized Benzolactams by Using Strong Electrophiles and Quantitative Evaluation of Ring-Size Dependency of the Cyclization Reaction Rate

Benzolactams with medium-sized rings were synthesized via the electrophilic aromatic substitution reaction of carbamoyl cations (R1R2N+═C═O) in good to high yields without dilution. These reactions were utilized to quantitatively examine the extent of retardation of medium-sized ring formation, compared to five- or six-membered ring formation. The order of reaction rates of formation of cyclic benzolactams is six- > five- > seven- > eight- > nine-membered ring at 25 °C. The present reaction provides a route to eight- A nd nine-membered benzolactams.

Iridium/f-Amphol-catalyzed Efficient Asymmetric Hydrogenation of Benzo-fused Cyclic Ketones

Iridium/f-Amphol-catalyzed asymmetric hydrogenation of various benzo-fused five to seven-membered cyclic ketones was successfully developed, affording a series of chiral benzo-fused cyclic alcohols with excellent results (75%–99% yields, 93%–>99% ee, and TON up to 297 000). The enantioenriched products can be employed as key intermediates or motifs for the synthesis of some important biologically active compounds, such as rasagiline mesylate TVP-1012 used for the treatment of Parkinson's disease, the enantiomer of anticonvulsant drug eslicarbazepine acetate (BIA 2-093). (Figure presented.).

Synthesis of novel building blocks of benzosuberone bearing coumarin moieties and their evaluation as potential anticancer agents

A series of novel benzosuberone bearing coumarin moieties 5a-c have been synthesized and their structures were determined by analytical and spectral (FT-IR, 1H NMR, 13C NMR, HRMS) studies. The newly synthesized compounds were evaluated for their cytotoxicity against four human cancer cell lines, A549 (Human alveolar adenocarcinoma cell line), HeLa (Human cervical cancer cell line), MDA-MB-231 (Human breast adenocarcinoma cell line), MCF-7 (Human breast adenocarcinoma cell line) and normal cell line HEK293 (Human embryonic kidney cell line). Compound 5a exhibited promising cytotoxicity with IC50 values ranging from 3.35 to 16.79 μM against all the cancer cell lines like A549, HeLa, MCF-7 and MDA-MB-231, while compound 5c showed significant cytotoxicity against HeLa and MDA-MB-231 with IC50 values of 6.72 and 4.87, respectively.

Increasing the open circuit voltage of bulk-heterojunction solar cells by raising the LUMO level of the acceptor

We report the synthesis, characterization, and electrochemical properties of ten new fullerene derivatives for usage in organic solar cells. The phenyl ring of PCBM was substituted with electron-donating and electron-withdrawing substituents to study thei

Ring enlargement of eight- and nine-membered cyclic sulfonamide derivatives in reactions with 3-amino-2H-azirines

The reactions of 3-dimethylamino-2H-azirines (1) with 3,4,5,6- tetrahydro-8,9-dimethoxy-2H-1,2-benzothiazocin-3-one 1,1-dioxide (6a) in acetonitrile gave the correspondingly substituted 3-dimethylamino- 4,5,6,7,8,9-hexahydrobenzo-1-thia-2,5-diazacyclounde

Synthesis and in vitro antibacterial activities of novel conformationally restricted hygromycin A analogues

The preparation of semisynthetic conformationally restricted hygromycin A analogues are described. Antibacterial results from these compounds suggest active conformations for this class of agents.

PHARMACOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME

Pharmacologically active catechol derivatives of formula I I wherein R1 and R2 independently comprise hydrogen, alkyl, acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcabamoyl or taken together form a lower alkylidene or cycloalkylidene, X comprises an electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, aldehyde, caboxyl or trifluoromethyl and R3 comprises hydrogen, halogen, hydroxy alkyl, amino, nitro, cyano, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkyl carbonyl, aralkylidene carbonyl or carboxyl or a group selected from wherein R4 comprises hydrogen, alkyl, cyano, carboxyl or acyl and R5 comprises hydrogen, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, optionally substituted aroyl or heteroaroyl, hydroxyalkyl or carboxyalkyl or R4 and R5 together form a five to seven membered substituted cycloalkanone ring; -(CO)n(CH2)m-COR wherein n is 0-1 and m is 0-7 and R comprises hydroxy, alkyl, carboxyalkyl, optionally substituted alkene, alkoxy or optionally substituted amino; wherein R8 and R9 independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or together form an optionally substituted piperidyl group; -NH-CO-R10 wherein R10 comprises a substituted alkyl group